CALDOLOR® (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT
MWN-AI** Summary
Cumberland Pharmaceuticals Inc. announced a significant development regarding its Caldolor® (ibuprofen) Injection, as the Centers for Medicare & Medicaid Services (CMS) has issued a permanent J-code (J1741) linked to a reimbursement price. This update aligns with the increasing demand for non-opioid alternatives in pain management amid the ongoing opioid crisis in the United States. Caldolor provides healthcare providers with a CMS-covered option for addressing pain and fever, thus aligning with opioid-sparing initiatives.
Caldolor is approved for managing mild to moderate pain, for use as an adjunct to opioid analgesics for moderate to severe pain, and plays a role in fever reduction. Its availability with an associated reimbursement price enhances accessibility for healthcare providers, encouraging them to consider non-opioid therapies that mitigate the risks of opioid dependence.
Cumberland Pharmaceuticals CEO, A.J. Kazimi, emphasized that this linkage not only serves as a clinically appropriate option for pain management but also supports broader efforts to minimize opioid exposure among patients. Healthcare providers are encouraged to adjust their internal systems and processes to incorporate the new J-code arrangements, ensuring efficient billing and coding practices.
Caldolor’s unique position as the first FDA-approved intravenous treatment for fever exemplifies its significance in clinical settings, though it does come with contraindications, including hypersensitivity to ibuprofen and other NSAIDs. For comprehensive prescribing and safety information, healthcare providers are referred to the product’s website.
Cumberland Pharmaceuticals remains committed to improving patient care by providing innovative healthcare solutions and expanding access to essential treatments like Caldolor, reaffirming its resolve to address pressing health issues related to pain management.
MWN-AI** Analysis
Cumberland Pharmaceuticals’ recent announcement regarding the permanent J-code assignment (J1741) for Caldolor® (ibuprofen) Injection has significant implications for its market positioning and growth prospects in the evolving landscape of pain management. This development indicates a clear regulatory endorsement of Caldolor as a viable non-opioid alternative, providing healthcare providers with a reimbursable option that aligns with the growing demand for opioid-sparing pain management therapies.
As the nation grapples with an opioid crisis, non-opioid medications like Caldolor represent a crucial strategy in pain management for both patients and healthcare systems. The J-code now linked with reimbursement opens avenues for wider utilization of Caldolor in clinical settings, particularly among practices emphasizing patient safety and adherence to pain management protocols. Healthcare providers are urged to update their systems to capitalize on this coding change, paving the way for improved reimbursement processes and potentially enhanced adoption rates.
From an investment standpoint, this update could lead to heightened interest in Cumberland Pharmaceuticals (Nasdaq: CPIX), particularly among those looking for companies positioned to benefit from shifts in pain management practices. The endorsement by the Centers for Medicare & Medicaid Services (CMS) not only endorses Caldolor's efficacy and safety but also strengthens Cumberland's competitive edge in the biopharmaceutical landscape focused on acute care and non-opioid therapies.
Moreover, the strategic importance of Caldolor extends beyond its primary function as a pain relief agent; it is backed by a wider portfolio of innovative therapies. These factors could bolster investor confidence, as they indicate a commitment to addressing substantial market needs and navigating regulatory frameworks effectively.
In summary, investors should consider the implications of the J-code assignment as part of their analysis of Cumberland Pharmaceuticals, weighing its potential for growth against broader trends in healthcare that prioritize non-opioid pain management solutions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
NASHVILLE, Tenn., Dec. 8, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), today announced an important update regarding its Caldolor® (ibuprofen) Injection. The product's permanent J-code, J1741, is now officially associated with a reimbursement price, providing healthcare providers with a CMS-covered, non-opioid option for managing pain and fever.
As the nation continues to face an opioid crisis, non-opioid alternatives, like Caldolor, play a critical role in reducing reliance on opioid medications, supporting safer pain management strategies for patients. With the reimbursement price now linked to J1741, providers can access a CMS-covered, non-opioid pain management option and align treatment strategies with opioid-sparing initiatives.
Caldolor J-Code Details:
- Product: Caldolor® (ibuprofen) Injection
- J-Code: J1741 – Injection, ibuprofen, 100 mg
- Status: Now associated with reimbursement price
"With Caldolor now linked to an established reimbursement price, healthcare providers have a reimbursable non-opioid alternative to help address pain management," said Cumberland Pharmaceuticals CEO A.J. Kazimi. "This update supports providers in making clinically appropriate decisions while contributing to efforts to reduce opioid exposure and reinforces our commitment to improving access to Caldolor and ensuring patients receive the pain management they need."
Providers are encouraged to update their internal systems, billing teams, and reimbursement processes to reflect this change. For additional support with coding, coverage, or payment questions, please contact your Cumberland Pharmaceuticals representative or email caldolor@cumberlandpharma.com.
About Caldolor® (ibuprofen) Injection
Caldolor is indicated in adults and pediatric patients for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever. It was the first FDA-approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with a history of asthma or other allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. For full prescribing and safety information, including boxed warning, visit www.caldolor.com.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on providing unique products that improve the quality of patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments. The company's portfolio of FDA-approved brands includes:
- Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning;
- Caldolor® (ibuprofen) injection, for the treatment of pain and fever;
- Kristalose® (lactulose) oral, a prescription laxative, for the treatment of constipation;
- Sancuso® (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;
- Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia;
- Vibativ® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections, and
- Talicia®(omeprazole magnesium, amoxicillin and rifabutin) oral capsule, for the treatment of H. pylori infection.
The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy, Systemic Sclerosis and Idiopathic Pulmonary Fibrosis.
For more information on Cumberland's approved products, including full prescribing information, please visit links to the individual product websites, which can be found on the company's website www.cumberlandpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's results of operations. These factors include market conditions, competition, an inability of manufacturers to produce Cumberland's products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure, natural disasters, public health epidemics, and other events beyond our control, as more fully discussed in the Company's most recent Form 10-K and subsequent 10-Qs as filed with the SEC. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.
SOURCE Cumberland Pharmaceuticals Inc.
FAQ**
How does Cumberland Pharmaceuticals Inc. (CPIX) plan to leverage the newly assigned J-code J1741 for Caldolor® to enhance its market penetration in the non-opioid pain management sector?
What strategies is Cumberland Pharmaceuticals Inc. (CPIX) implementing to educate healthcare providers about the reimbursement process for Caldolor® under the new J-code J1741?
Given the opioid crisis, how does Cumberland Pharmaceuticals Inc. (CPIX) envision the role of Caldolor® in transforming pain management practices within healthcare systems?
What are the expected financial implications for Cumberland Pharmaceuticals Inc. (CPIX) following the association of a reimbursement price with Caldolor® under J-code J1741?
**MWN-AI FAQ is based on asking OpenAI questions about Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX).
NASDAQ: CPIX
CPIX Trading
1.29% G/L:
$3.15 Last:
10,337 Volume:
$3.18 Open:
